Antibody Containment HR Protein 
XTalks
FEBRUARY 7, 2023
HR+/HER2- breast cancer is the most common type of breast cancer, with the National Cancer Institute (NCI) estimating 287,850 new cases of female breast cancer in 2022 alone. Despite decades of advances, people living with pre-treated HR+/HER2- metastatic breast cancer need new treatment options. months vs. 11.2
The Pharma Data
DECEMBER 29, 2020
First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19. NASDAQ: REGN) today announced encouraging initial data from an ongoing Phase 1/2/3 clinical trial of the Regeneron antibody cocktail, casirivimab and imdevimab, in hospitalized COVID-19 patients requiring low-flow oxygen. futility analysis).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
MARCH 20, 2021
Cell culture for virus isolation also remains a useful method for growing and studying viruses in research settings especially in the characterization of novel pathogenic viruses like SARS-CoV-2 although this requires more advanced containment facilities such as biosafety level 3 (BSL-3).
Drug Discovery World
JANUARY 9, 2024
2024 is anticipated to be a transformational year for the pharma industry, with new modalities like antibody drug conjugates and AI/machine learning providing therapies for patients with limited treatment options. The therapy has shown positive results in Phase III trials in both breast and lung cancer.
The Pharma Data
JANUARY 14, 2021
HR (95% CI): 0.68. HR (95% CI): 0.54 (0.33, 0.87). HR (95% CI): 0.44 (0.25, 0.77). HR (95% CI): 0.58; (0.35, 0.95); p=0.027. HR (95% CI): 0.44 (0.25, 0.77). HR (95% CI): 0.58; (0.35, 0.95); p=0.027.
The Pharma Data
MARCH 23, 2021
For OS and PFS, KEYTRUDA plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; 0.86]; p<0.0001) and reduced the risk of disease progression or death by 35% (HR=0.65 [95% CI, 0.55-0.76]; for the placebo arm, with a HR of 0.62 (95% CI, 0.49-0.78; for the placebo arm, with a HR of 0.86 (95% CI, 0.68-1.10).
The Pharma Data
JANUARY 4, 2021
months with Tecentriq alone; HR=0.30, 95% CI: 0.15–0.61). TIGIT and PD-L1 are proteins that play a role in suppression of the immune system. Tiragolumab is a monoclonal antibody designed to bind with TIGIT, a protein receptor on immune cells. Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1.
Expert insights. Personalized for you.
52 
Let's personalize your content